The Verdict First
Most supplements do not have strong evidence behind them. That is not opinion - it is what happens when you look at the actual clinical trial data instead of marketing copy. Out of the hundreds of supplement ingredients on the market, only a handful have the kind of evidence that would survive peer review at a major medical journal: multiple large randomized controlled trials, replicated results, clear mechanisms, and meaningful effect sizes.
We sorted every major supplement ingredient into three tiers based on the quality and depth of the clinical evidence. Tier 1 ingredients have strong, consistent support from multiple RCTs and meta-analyses. Tier 2 ingredients show real promise but need more or better research. Tier 3 is where marketing has outrun science - popular products with thin or negative evidence.
This is not a ranking of what is "natural" or "safe." It is a ranking of what has been proven to do what it claims. If your supplement is in Tier 3, it does not mean it is dangerous. It means nobody has adequately proven it works. That matters when you are spending money on it.
For a deeper look at how we evaluate evidence across the site, see our full scoring methodology.
Tier 1: Strong Evidence - Multiple Large RCTs and Meta-Analyses
These ingredients have been studied extensively in human trials. The effects are consistent, replicable, and meaningful. If you are going to spend money on supplements, start here.
Creatine Monohydrate
Creatine is the single most evidence-backed supplement ingredient in existence. The International Society of Sports Nutrition has called it the most effective ergogenic nutritional supplement currently available for increasing high-intensity exercise capacity and lean body mass.
A 2003 meta-analysis in the Journal of Strength and Conditioning Research covering 22 studies found that creatine supplementation increased strength performance by 8% and weightlifting performance by 14% compared to placebo. A more recent 2017 review by the ISSN confirmed these findings and extended them: creatine improves recovery, thermoregulation, and may reduce injury severity. The effect size for strength gains is large and consistent across populations, ages, and training statuses.
Emerging evidence also supports cognitive benefits. A 2018 systematic review in Experimental Gerontology found that creatine supplementation improved short-term memory and reasoning in healthy adults, with larger effects during stressful conditions like sleep deprivation. The effective dose is 3-5g per day of creatine monohydrate. No loading phase is required - it just takes 3-4 weeks to saturate muscle stores without one.
See our full creatine monohydrate scorecard for product comparisons.
Omega-3 Fatty Acids (EPA/DHA)
The evidence for omega-3 supplementation is strong for specific outcomes and weaker for others. The distinction matters.
For triglyceride reduction, the evidence is unambiguous. A 2012 Cochrane meta-analysis of 47 RCTs confirmed that omega-3 supplementation reduces triglycerides by 15-30% at doses of 2-4g EPA+DHA per day. The REDUCE-IT trial (2019, NEJM) showed that 4g of icosapentaethyl (purified EPA) reduced major cardiovascular events by 25% in statin-treated patients with elevated triglycerides. This was a landmark trial with over 8,000 participants.
For general cardiovascular protection in healthy people, the picture is more nuanced. A 2020 Cochrane review found that increasing EPA and DHA slightly reduces risk of coronary heart events and cardiovascular mortality but has little or no effect on all-cause mortality. The benefit is real but modest in low-risk populations.
For inflammation, a 2018 meta-analysis in Atherosclerosis covering 68 RCTs confirmed that omega-3 supplementation reduces CRP, IL-6, and TNF-alpha levels - measurable anti-inflammatory effects across thousands of participants.
The effective dose depends on the goal: 1-2g EPA+DHA per day for general health, 2-4g for triglyceride management (under medical supervision). See our fish oil scorecard for cost-per-effective-dose comparisons.
Vitamin D3
Vitamin D sits in Tier 1 with a major caveat: the strong evidence is primarily for correcting deficiency, not for supplementing on top of adequate levels. An estimated 42% of U.S. adults are vitamin D deficient, according to NHANES data, which is why supplementation matters at a population level.
For bone health, the evidence is robust. A 2011 meta-analysis in the NEJM of 31,022 participants found that vitamin D supplementation (at 800+ IU/day) reduced hip fracture risk by 30% and non-vertebral fracture risk by 14%, but only at adequate doses and in combination with calcium. For immune function, a 2017 meta-analysis in the BMJ of 25 RCTs with over 11,000 participants found that vitamin D supplementation reduced the risk of acute respiratory tract infections by 12% overall, and by 70% in participants with severe deficiency (below 10 ng/mL).
Where the evidence gets thinner: vitamin D supplementation in people who already have adequate levels (30+ ng/mL). The VITAL trial (2019, NEJM), which randomized 25,871 adults to 2,000 IU/day vitamin D3 or placebo, found no significant reduction in cancer or cardiovascular events in a general population. The takeaway: test your levels. Supplement if you are deficient. Do not assume more is better.
See our vitamin D3 scorecard for products scored by cost per effective dose.
Magnesium
Roughly half of U.S. adults fall short of the recommended daily magnesium intake. This is not a fringe claim - it is confirmed by NHANES dietary surveys. Because magnesium is involved in over 300 enzymatic reactions, subclinical deficiency shows up as poor sleep, muscle cramps, anxiety, and fatigue.
For sleep, a 2012 double-blind RCT in elderly subjects with insomnia found that 500mg magnesium daily improved sleep time, sleep efficiency, and serum melatonin levels. For blood pressure, a 2016 meta-analysis in Hypertension of 34 RCTs with 2,028 participants found that magnesium supplementation at a median dose of 368mg/day reduced systolic blood pressure by 2.0 mmHg and diastolic by 1.78 mmHg - a small but statistically significant and clinically relevant effect. For a comparable mild-BP play with a different mechanism, olive leaf extract at 500-1000mg/day delivered roughly 4-12 mmHg systolic reductions in the Susalit and Razmpoosh meta-analytic data.
For mood, a 2017 randomized trial in PLOS ONE found that 248mg elemental magnesium daily improved depression scores comparably to some antidepressants in adults with mild-to-moderate depression. The form matters: magnesium glycinate and magnesium threonate have better absorption and tolerability than magnesium oxide, which is cheap but poorly absorbed. The two forms are not interchangeable; see our glycinate vs L-threonate comparison for which one fits which goal.
See our magnesium glycinate scorecard for detailed product comparisons.
Caffeine
Including caffeine on a supplement list feels almost trivial, but it deserves mention because it is the most widely used performance-enhancing substance on Earth and the evidence is overwhelming. A 2019 umbrella review in the British Journal of Sports Medicine covering 21 published meta-analyses confirmed that caffeine improves muscular endurance, muscular strength, anaerobic power, and aerobic endurance. Effect sizes are moderate to large. The effective dose is 3-6mg per kg of body weight, taken 30-60 minutes before activity.
For cognitive performance, a 2016 meta-analysis confirmed improvements in attention, reaction time, and alertness. The effects are dose-dependent and subject to tolerance. If you already drink coffee daily, supplemental caffeine pills offer minimal additional benefit.
Melatonin (Low Dose)
Melatonin works for sleep onset. The evidence is clear and consistent. A 2013 meta-analysis in PLOS ONE of 19 RCTs found it reduced sleep onset latency by 7 minutes and improved overall sleep quality. The critical nuance is dose: 0.3-1mg is the physiologically optimal range. Most products sell 5-10mg doses, which overshoot the body's natural nocturnal melatonin level and can cause grogginess and vivid dreams.
A landmark MIT study established 0.3mg as sufficient to restore normal nocturnal melatonin levels. Higher is not better here - it is worse. See our melatonin scorecard for products that offer appropriate dosing.
Two adjacent sleep botanicals get pulled into Tier 1 conversations and do not belong there. Valerian root is widely marketed for insomnia but the 2015 Sleep Medicine Reviews meta-analysis found no significant difference from placebo on any objective sleep measure. Apigenin (the chamomile flavone Andrew Huberman put on the map) has interesting GABA-receptor binding data in animals but no controlled human sleep trials at the doses sold; the human evidence comes from chamomile tea, not isolated apigenin capsules.
Psyllium Husk / Fiber Supplements
Fiber supplementation is boring. It also works. A 2018 meta-analysis in the American Journal of Clinical Nutrition found that psyllium supplementation reduced LDL cholesterol by 0.33 mmol/L (approximately 13 mg/dL) - a meaningful reduction. For blood sugar, a 2015 meta-analysis in the Journal of the American Board of Family Medicine showed that psyllium reduced fasting glucose by 37 mg/dL in diabetic patients, which is clinically significant.
For gut health, the FDA has approved a qualified health claim that psyllium may reduce the risk of heart disease, based on the cholesterol evidence. The effective dose is 5-10g per day, taken with plenty of water.
Tier 2: Promising but Needs Better Evidence
These ingredients have real mechanisms, real studies, and real results - but the evidence base has gaps. Studies are often small, short-term, or have methodological limitations. They are worth considering but carry more uncertainty than Tier 1.
Taurine
Taurine has earned Tier 2 placement on the back of two consistent evidence streams. A 2018 meta-analysis in Current Hypertension Reports found roughly 3 mmHg systolic and diastolic reductions across 7 RCTs, with a 2016 prehypertension trial showing 7.2 mmHg systolic drops at 1.6 g/day. A separate Waldron 2018 meta-analysis in Sports Medicine confirmed a small but real endurance benefit at 1-6 g pre-exercise. The viral 2023 Science paper on taurine and aging is interesting biology but the human longevity data is not there yet. See our taurine scorecard for product-by-product grades. Olive leaf extract sits one tier lower with similar BP-lowering magnitude (3-12 mmHg systolic) but a thinner trial base, mostly anchored to one head-to-head vs captopril and a 12-trial meta-analysis.
Ashwagandha
Ashwagandha has good RCT evidence for stress and cortisol reduction. A 2020 meta-analysis of five RCTs found significant anxiety reduction. A 2012 double-blind trial showed that 300mg of KSM-66 twice daily reduced serum cortisol by 30% compared to placebo. The results are consistent and the mechanism (modulation of the HPA axis) is plausible.
Why Tier 2 and not Tier 1? Most trials are small (30-100 participants), short (8-12 weeks), and many are funded by the KSM-66 manufacturer. We need larger, independent, long-term trials to confirm these findings. The existing evidence is promising but not yet definitive. See our ashwagandha scorecard for product comparisons.
Berberine
Berberine has a real mechanism - AMPK activation - and measurable effects on blood sugar. A 2008 study in Metabolism found that 500mg berberine three times daily reduced HbA1c by 0.9% in patients with type 2 diabetes, comparable to metformin in the same trial. A 2020 meta-analysis confirmed modest weight loss effects of about 2.3 kg over 12 weeks.
The limitations: most trials are conducted in China with relatively small sample sizes, there are few long-term safety studies beyond 6 months, and the GI side effects (diarrhea, cramping) are significant enough that some participants drop out. The evidence for metabolic health is real, but we need Western replication trials and long-term data. See our berberine scorecard.
Curcumin / Turmeric
Curcumin has genuine anti-inflammatory properties. The problem is getting enough of it into your bloodstream. Standard turmeric powder has roughly 3% curcumin, and curcumin has extremely low oral bioavailability - less than 1% is absorbed without enhancement.
When bioavailability-enhanced formulations (piperine, liposomal, phytosome) are used, the evidence improves. A 2016 meta-analysis in the Journal of Medicinal Food of 8 RCTs found that curcumin supplementation significantly reduced CRP (an inflammation marker). For joint pain, a 2014 RCT found that curcumin (1,500mg/day Meriva phytosome formulation) was as effective as 1,200mg ibuprofen for osteoarthritis pain after 4 weeks.
Tier 2 because: the bioavailability problem makes it hard to know which products will actually deliver meaningful blood levels, and many trials use enhanced formulations that are not representative of what most consumers buy. Our turmeric/curcumin scorecard factors in bioavailability enhancement when scoring products.
Probiotics
The probiotic evidence is wildly strain-dependent. Lumping all probiotics together is like lumping all medications together. Saccharomyces boulardii has strong evidence for antibiotic-associated diarrhea (2015 Cochrane review). Lactobacillus rhamnosus GG has good evidence for infectious diarrhea in children. Many multi-strain products have weak or no evidence for their specific combination.
A 2018 systematic review found that probiotics as a class show small but significant benefits for IBS symptoms, but the heterogeneity across studies makes it impossible to generalize. Probiotics sit in Tier 2 because individual strains have strong evidence, but the category as a whole is too fragmented for a blanket recommendation. See our probiotic scorecard.
CoQ10
CoQ10 has two evidence stories. For statin-associated muscle symptoms, a 2018 meta-analysis in the Journal of the American Heart Association of 12 RCTs found that CoQ10 supplementation reduced statin-related muscle pain by a small but statistically significant degree. For heart failure, a 2014 trial (Q-SYMBIO) of 420 patients with chronic heart failure showed that CoQ10 (100mg three times daily) reduced cardiovascular mortality and hospitalizations over 2 years.
Tier 2 because the statin-myopathy evidence is mixed across studies, and Q-SYMBIO - while impressive - is a single trial that needs replication. The ubiquinol form has better absorption than ubiquinone, which matters for dosing. See our CoQ10 scorecard.
Spirulina
Spirulina earns Tier 2 placement on a 2016 meta-analysis (Serban, 7 RCTs) showing meaningful LDL and triglyceride reductions and a 2021 BP meta-analysis (Machowiec, 5 RCTs) showing roughly 4-7 mmHg drops in hypertensive patients. The catch is dose: clinical effects show up at 4-8g/day, not the 500mg printed on most labels. Source quality matters more than brand - Hawaiian, Californian, or Parry-sourced products publish the heavy-metal testing that wild-harvested Klamath Lake products do not. See our spirulina scorecard.
Garlic Extract (Aged or Allicin-Standardized)
Multiple meta-analyses support a modest blood pressure reduction (roughly 7-9 mmHg systolic in hypertensives) at 600-1500mg/day of aged garlic extract or enteric-coated allicin product. The cholesterol effect is real but small (around 9 mg/dL LDL drop). The form matters: plain garlic powder capsules without enteric coating lose allicin to stomach acid. See our garlic extract scorecard for product comparisons.
Red Yeast Rice (with the Statin Caveat)
Red yeast rice containing meaningful monacolin K is the most-studied non-prescription LDL-lowering supplement, with multiple RCTs showing 20-35 mg/dL LDL reductions at 1200-2400 mg/day. The catch: monacolin K is chemically identical to lovastatin, so the effect is real because the molecule is a statin - and the side effect profile (muscle pain, liver enzyme elevation, drug interactions) is the same. US-sold products that have been reformulated to remove monacolin K have correspondingly little effect. See our red yeast rice scorecard.
Tart Cherry (Recovery and Sleep)
Tart cherry sits in this moderate-evidence tier. The exercise recovery RCTs (Howatson 2010 marathons, Connolly 2006 eccentric training, Bell 2015 cycling) are reasonably consistent at reducing strength loss and inflammation markers post-exercise, with CherryPure standardized extract or 16oz/day Montmorency juice as the trial-tested formats. The sleep evidence is thinner but real - Pigeon 2010 in older adults with insomnia, Howatson 2012 on melatonin and sleep efficiency. The gout claims widely promoted by retailers rest mostly on a single observational case-crossover study (Zhang 2012), which is why we keep tart cherry out of any "best for joint pain" framing despite the marketing pressure to include it.
See our tart cherry scorecard for the CherryPure-vs-juice cost math at the trial dose.
Collagen Peptides (for Skin)
Collagen supplementation for skin hydration has surprisingly decent evidence. A 2019 meta-analysis in the Journal of Drugs in Dermatology covering 11 RCTs and 805 participants found that collagen supplementation improved skin hydration and elasticity after 8-12 weeks. The effect is modest but measurable and consistent across studies using hydrolyzed collagen peptides at 2.5-10g per day.
Why Tier 2: the proposed mechanism (oral collagen peptides signaling fibroblasts to increase collagen synthesis) is plausible but not fully confirmed, many trials are industry-funded, and the improvements, while statistically significant, are modest enough that most people would not notice dramatic visual changes. See our collagen scorecard.
Tier 3: Mostly Marketing, Limited or Negative Evidence
These are the categories where consumer spending vastly exceeds what the evidence supports. Some of these ingredients have theoretical mechanisms. Some have a single promising study that gets cited in every ad. None have the consistent, replicated evidence that would justify the prices being charged.
Spending money on Tier 3 supplements instead of Tier 1 supplements is one of the most common mistakes we see. If you are budgeting for supplements, start with our guide on whether you need supplements at all, and if you do, spend on Tier 1 first.
Most Proprietary Blends and "Stacks"
Proprietary blends exist for one reason: they allow manufacturers to list ingredients without disclosing how much of each ingredient is in the product. This means a product can list 15 "clinically studied" ingredients while including meaningful doses of zero of them. If a product uses a proprietary blend, you cannot calculate cost per clinically effective dose, because you do not know the dose. Skip these.
BCAAs (Branched-Chain Amino Acids)
BCAAs were once a staple in gym bags. The evidence does not support that. A 2017 review in the Journal of the International Society of Sports Nutrition found that BCAA supplementation alone does not stimulate muscle protein synthesis any more effectively than simply eating adequate protein. If you consume 1.6g+ protein per kg of body weight daily (which most people focused on fitness already do), BCAAs are redundant. You are paying a premium for three amino acids you already got from your chicken breast.
Most "Testosterone Boosters"
The testosterone booster category is where supplement marketing is at its most detached from evidence. A 2019 review in the World Journal of Men's Health examined popular testosterone-boosting ingredients and found that the majority had no evidence of increasing testosterone in healthy men. Tribulus terrestris, DHEA, D-aspartic acid, and fenugreek all showed either no effect or effects too small to be clinically meaningful. Our fenugreek scorecard goes deeper on this - the testosterone story is mixed but the blood sugar and HbA1c evidence is meaningfully stronger. The few ingredients with any signal (like ashwagandha and zinc) work primarily by correcting deficiencies, not by boosting testosterone above normal levels. Shilajit, a newer entrant in this category, has an Indian RCT signal at 250 mg twice daily that has not been independently replicated. Agmatine sulfate belongs to the same evidence-thin shelf for pre-workout pump claims.
If a product promises to "naturally boost testosterone by 300%," the evidence says otherwise. Some claims rest on a single small trial - boron's testosterone story comes from one 8-man week-long study, and we treat it as early signal, not supported. The bone-metabolism evidence at 3-6 mg/day is older but more credible.
Hormonal-Cycle Herbs (Mixed Evidence Within Category)
Women's hormonal-cycle herbs are not all created equal. Vitex (chasteberry) stands out as the one with credible RCT evidence, including the 2001 Schellenberg BMJ trial at n=178 supporting use for premenstrual cycle complaints and cyclical mastalgia. The mechanism (dopaminergic prolactin suppression) is real and the standardized Ze 440 extract at 20 mg/day has been replicated. DIM (diindolylmethane) has a verified biomarker effect on the 2-OH:16-alpha-OH estrogen metabolite ratio but the clinical-endpoint evidence (breast cancer, hormonal acne, "estrogen dominance") is much thinner than the marketing implies; only the BR-DIM absorbable form has meaningful trial data. Myo-inositol at 4 g/day has multiple positive RCTs for PCOS metabolic and ovulatory support and sits closer to Tier 1.5 within this group. Evening primrose oil sits at the bottom of this category - the 2013 Cochrane review concluded oral EPO "lacks effect on eczema," the Blommers 2002 cyclical-mastalgia trial found no benefit over corn-oil placebo, and 2021 meta-analyses describe it as "comparable to placebo" for breast pain. The cultural reputation has run far ahead of the data.
Adaptogenic and Functional Mushrooms (Tier 2 Floor, Tier 3 Ceiling)
Three popular medicinal mushrooms have legitimate but modest human evidence and three have essentially none. Cordyceps earns a Tier 2 floor from two small RCTs - Chen 2010 in older adults using CS-4 mycelium and Hirsch 2017 in trained adults using Cordyceps militaris at 4 g/day - both showing modest improvements in ventilatory threshold, time to exhaustion, and VO2max. The exercise-tolerance signal is real but the rest of the marketing (libido, "anti-aging," general energy) is mostly animal data. Reishi mushroom sits next to it on the strength of the 2016 Cochrane review of 5 RCTs (n=373) showing improved immune cell counts and quality of life as a chemo-radiation adjunct, and the Tang 2005 RCT (n=132) showing modest fatigue reduction in chronic neurasthenia. Standalone benefit in healthy adults is thinner.
Chaga mushroom drops to Tier 3. Almost everything written about chaga - anticancer, blood-sugar, anti-inflammatory - comes from cell culture and rodent models, not human trials. Memorial Sloan Kettering states plainly that "the safety and efficacy of chaga have yet to be evaluated in clinical studies." The chemistry is interesting (very high ORAC, melanin, betulin) but the in-vitro signal has not translated. Worse, chaga is unusually high in oxalates and multiple case reports document end-stage renal failure in chronic users (Kikuchi 2014, Lee 2020). Anyone with kidney concerns should not take it.
"Superfood" Greens Powders
Moringa is the textbook superfood-marketing case. Sold as a "miracle tree," the actual human evidence is much thinner than the marketing suggests - most positive trials are small, unblinded, and run in resource-limited populations where baseline nutrition can confound any supplement effect. The 2025 cardiometabolic meta-analysis found no significant pooled effect on HbA1c or fasting glucose. The clearest defensible use case is as an iron-and-vitamin-rich green powder for people with genuinely inadequate dark-leafy-vegetable intake, with the caveat that heavy metal contamination from soil (lead, cadmium, arsenic) is a real concern - choose USDA Organic plus third-party testing if you buy at all.
Huperzine A (Pharmacology Without the Pharmacy)
Huperzine A is a serious-pharmacology supplement, not a casual nootropic. Mechanistically it is a reversible acetylcholinesterase inhibitor in the same drug class as donepezil, galantamine, and rivastigmine - the prescription Alzheimer's medications. The Yang 2013 meta-analysis (20 RCTs, 1,823 patients) showed MMSE and ADL improvements in Alzheimer's, but most included trials had high risk of bias, and the strongest Western trial (Rafii 2011 ADCS phase II, n=210) was negative on its primary endpoint. Healthy-adult cognition data is thin - the most-cited trial is in 34 Chinese middle school students. The cholinergic side effect profile, the 10-14 hour half-life, and the additive interaction with prescribed AChE inhibitors all argue against casual nootropic use. The Tier 3 placement is for the marketing context (a focus stack ingredient), not the underlying compound, which has a real dementia-treatment evidence base requiring physician supervision.
Most "Fat Burner" Supplements
Fat burner supplements typically combine caffeine with a collection of herbal extracts like green tea extract, garcinia cambogia, raspberry ketones, and CLA. The caffeine provides a mild metabolic boost (which you could get from coffee). The rest contributes very little. A 2021 review of fat burner ingredients found that most produce either no measurable effect on body composition or effects so small as to be clinically irrelevant. The only exception is caffeine itself, which sits in Tier 1 for performance - not for fat loss. MCT oil shows up in keto and "fat-burning coffee" marketing on the same premise: medium-chain triglycerides are oxidized faster than long-chain fats, so adding them must accelerate fat loss. The human data does not support that translation in non-deficient adults eating a normal mixed diet, and the calories you add from a tablespoon of MCT oil are real even if the metabolic story is not. L-carnitine, often marketed as a fat-burning amino acid, fits the same pattern: meta-analyses show small body-composition effects in overweight populations on calorie restriction, with little benefit in lean trained subjects. It has stronger (still modest) evidence as a heart-failure adjunct and for exercise recovery in the L-carnitine L-tartrate form than for fat loss.
Resveratrol (for Longevity)
Resveratrol is the textbook example of a supplement whose human evidence has not caught up with its hype. Animal studies in mice and yeast suggested sirtuin activation and lifespan extension, which fueled the David Sinclair longevity narrative. Human trials show modest signals on insulin sensitivity, endothelial function, and systolic blood pressure in metabolic and cardiovascular populations, not lifespan or "anti-aging" outcomes. Bioavailability is poor (under 1% of trans-resveratrol crosses the gut intact), and doses above 1 g/day commonly cause GI side effects. There is a real cardiometabolic story at modest effect sizes; there is no human longevity story. See our resveratrol scorecard for the trans-resveratrol-mg-per-cap distinction that most product labels obscure. The same evidence-vs-marketing gap applies to the NAD+ precursor category; our NMN vs NR longevity walk-through covers what those compounds actually do (raise blood NAD+) versus what they are sold as doing.
Collagen for Joint Health
This is a separate claim from skin health, and the evidence is weaker. While UC-II (undenatured type II collagen) has a small number of studies suggesting modest improvement in joint comfort, hydrolyzed collagen peptides - the most common form sold - have very limited evidence for joint-specific outcomes. The mechanism (oral collagen surviving digestion and reaching joint tissue) is poorly established. If your goal is joint health, glucosamine sulfate has a stronger evidence base.
Detox and Cleanse Supplements
Your liver and kidneys detoxify your body. They do this continuously without supplemental assistance. There is no clinical evidence that any "detox" or "cleanse" supplement improves the body's detoxification processes. A 2015 review in the Journal of Human Nutrition and Dietetics found no clinical evidence to support the use of commercial detox diets for toxin elimination or weight management. This is one of the clearest cases of marketing with no evidence behind it. The popular candidates here - activated charcoal, milk thistle, and chlorella - all rest on animal data or in-vitro mechanism, not controlled human chelation trials.
"Natural Dopamine" Mucuna Marketing
Mucuna pruriens is increasingly marketed as a "natural dopamine" focus or motivation supplement. The honest framing: mucuna is essentially a botanical source of L-DOPA, the same molecule used as a prescription Parkinson's drug. The controlled-trial evidence is confined to Parkinson's disease (where it is genuinely useful) and a small fertility signal in subfertile men. There is no trial support for casual nootropic, mood, or motivation use, and the safety profile - dyskinesia risk, MAOI and antipsychotic interactions, blood pressure effects - is wrong for daily wellness supplementation. The Tier 3 placement is for the marketing claim, not the underlying compound.
How to Use This Ranking
This tier list is a starting point. The right supplement for you depends on your specific situation - your diet, your lab results, your health goals, and what you are already getting from food. A Tier 1 supplement can still be wrong for you if you do not need it. A Tier 2 supplement might be right for you if it targets your specific deficiency or condition.
Three principles for spending your supplement budget wisely:
- Address deficiencies first. If you are low in vitamin D, magnesium, or omega-3s (and statistically, many people are), fix those before adding anything exotic. This is where the cost-per-effective-dose math matters most.
- Demand third-party testing. At every tier level, choose products with USP, NSF, or independent lab verification. Our supplement buying guide explains what to look for.
- Be skeptical of stacks. Multi-ingredient products almost always underdose individual ingredients. A product with 20 ingredients at sub-clinical doses is worse than a product with one ingredient at the right dose.
Every supplement we score on this site is evaluated using the same four-factor rubric: evidence quality, purity and testing, cost per clinically effective dose, and label transparency. You can explore our full database starting from the supplement index, or see how the cost factor plays out catalog-wide in our cost-per-effective-dose study of all 155 supplements.
Sources
- Kreider RB, Kalman DS, Antonio J, et al. International Society of Sports Nutrition position stand: safety and efficacy of creatine supplementation in exercise, sport, and medicine. Journal of the International Society of Sports Nutrition. 2017;14:18. PMID 28615996.
- Bhatt DL, Steg PG, Miller M, et al. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia (REDUCE-IT). New England Journal of Medicine. 2019;380(1):11-22. PMID 30415628.
- Martineau AR, Jolliffe DA, Hooper RL, et al. Vitamin D supplementation to prevent acute respiratory tract infections: systematic review and meta-analysis of individual participant data. BMJ. 2017;356:i6583. PMID 28202713.
- Mortensen SA, Rosenfeldt F, Kumar A, et al. The effect of coenzyme Q10 on morbidity and mortality in chronic heart failure: results from Q-SYMBIO. JACC: Heart Failure. 2014;2(6):641-649. PMID 25282031.
- Jovanovski E, Yashpal S, Komishon A, et al. Effect of psyllium (Plantago ovata) fiber on LDL cholesterol and alternative lipid targets: a systematic review and meta-analysis of randomized controlled trials. American Journal of Clinical Nutrition. 2018;108(5):922-932. PMID 30239559.
- Hibbeln JR, Ferguson TA, Blasbalg TL. Omega-3 fatty acid deficiencies in neurodevelopment, aggression and autonomic dysregulation: opportunities for intervention. International Review of Psychiatry. 2006;18(2):107-118. PMID 16777665.
- Jager R, Kerksick CM, Campbell BI, et al. International Society of Sports Nutrition position stand: protein and exercise. Journal of the International Society of Sports Nutrition. 2017;14:20. PMID 28642676.
- Santos HO, Teixeira FJ, Schoenfeld BJ. Dietary vs. pharmacological doses of zinc: a clinical review. Clinical Nutrition. 2020;39(5):1345-1353. PMID 31303527.